Adaptin Bio (APTN) Net Cash Flow (2024 - 2026)
Adaptin Bio's (APTN) quarterly Net Cash Flow came in at $369179.0 in Q2 2026, up 136.1% year-over-year from $156366.8 in Q2 2025, and up 333.86% quarter-over-quarter from -$157865.0 in Q1 2026.
Powered by 
Analysis
Adaptin Bio (APTN) Net Cash Flow (2024 - 2026) Analysis & Trends
Adaptin Bio has disclosed Net Cash Flow across 3 years of filings, most recently posting $369179.0 for Q2 2026.
- In Q2 2026, Net Cash Flow rose 136.1% year-over-year to $369179.0; the TTM figure through Jun 2026 stood at -$681031.0 (down 151.29% YoY), while the FY2025 annual figure was $425089.0, up 1349.28% from the prior year.
- Net Cash Flow came in at $369179.0 for Q2 2026 at Adaptin Bio, up from -$157865.0 in the prior quarter.
- In the past five years, Net Cash Flow ranged from a high of $2.3 million in Q1 2025 to a low of -$1.0 million in Q2 2025.
- Average Net Cash Flow over 3 years is $66573.4, with a median of -$40459.0 recorded in 2024.
- The largest YoY upside for Net Cash Flow was 767160.33% in 2025 against a maximum downside of 5564.07% in 2025.
- Over 3 years, Net Cash Flow stood at -$81223.0 in 2024, then plunged by 47.64% to -$119915.0 in 2025, then soared by 407.87% to $369179.0 in 2026.
- Per Business Quant data, the three most recent Net Cash Flow figures were $369179.0 in Q2 2026, -$157865.0 in Q1 2026, and -$119915.0 in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Krystal Biotech | 10.27 Bn | 9.43 Bn | 112.79 Mn | -71.74 Mn |
| 2 | CRISPR Therapeutics AG | 5.17 Bn | 5.17 Bn | - | -131.98 Mn |
| 3 | Iovance Biotherapeutics | 3.79 Bn | 3.49 Bn | 55.72 Mn | -85.58 Mn |
| 4 | Legend Biotech | 3.68 Bn | 2.71 Bn | 251.50 Mn | 26.80 Mn |
| 5 | uniQure | 3.05 Bn | 3.05 Bn | 5.49 Mn | 273.80 Mn |
| 6 | Beam Therapeutics | 2.65 Bn | 2.65 Bn | - | -68.45 Mn |
| 7 | Precigen | 2.44 Bn | 2.44 Bn | 52.17 Mn | 8.85 Mn |
| 8 | Sarepta Therapeutics | 2.33 Bn | 1.53 Bn | 251.87 Mn | 103.70 Mn |
| 9 | Vericel | 1.99 Bn | 1.83 Bn | 56.40 Mn | 16.06 Mn |
| 10 | Adaptin Bio | 56.76 Mn | 56.09 Mn | - | 369,179.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 369,179.00 |
| Mar 31, 2026 | -157,865.00 |
| Dec 31, 2025 | -119,915.00 |
| Sep 30, 2025 | -772,430.00 |
| Jun 30, 2025 | -1.02 Mn |
| Mar 31, 2025 | 2.34 Mn |
| Dec 31, 2024 | -81,223.00 |
| Sep 30, 2024 | 91,532.00 |
| Jun 30, 2024 | 18,717.00 |
| Mar 31, 2024 | 305.00 |